ModernMedicine Resource Center More Topics

generics

Medicare drug spending spike shows need for genericsAn exclusive Associated Press report found that Medicare’s spending on certain drugs soared by 85% in two years.
What the new biosimilar means for U.S. healthcarePhysicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.
Biosimilar naming method questionedFDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring.
Study: Biosimilars as safe as branded drugsNew study finds that biosimilar medications for arthritis and other diseases areas safe and effective as their brand-name counterparts.
Global generics drug market to grow 10% annuallyPatents expire, competition rises, and outsourcing expands.
New bill aims to support generic, biosimilar drug competitionThe CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development.
How Walmart plans to save on genericsWalmart has decided to put all its eggs in a really big basket.
Pharmacists seek fairness in generics reimbursementPBMs have dodged state-mandated requirements for transparency in generics drug pricing, so many states are rewriting their laws.
FDA generics backlog improves, although criticism continuesWhile many groups are criticizing the FDA backlog of generic drug approvals, the agency has released the numbers on approvals and tentative approvals for 2015.
Generic treatment for chronic myeloid leukemia could save millionsFive years of imatinib treatment for CML = >$100,000 saved per patient.